AbCellera Biologics Inc. (ABCL) financial statements (2022 and earlier)

Company profile

Business Address 2215 YUKON STREET
VANCOUVER, BC V5Y 0A1
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments476518793686
Cash and cash equivalents476518793686
Receivables14 65216
Other current assets21776
Other undisclosed current assets418279  
Total current assets:930804864908
Noncurrent Assets
Property, plant and equipment112928735
Long-term investments and receivables50484332
Long-term investments50484332
Intangible assets, net (including goodwill)196198142144
Goodwill48493232
Intangible assets, net (excluding goodwill)148149110113
Other noncurrent assets31321610
Total noncurrent assets:389369288221
TOTAL ASSETS:1,3191,1731,1521,129
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:15964
Accrued liabilities2312420
Employee-related liabilities442 
Taxes payable36761
Other undisclosed accounts payable and accrued liabilities(47)(2)(26)(18)
Deferred revenue861111
Deferred compensation liability   0
Business combination, contingent consideration, liability23121214
Other undisclosed current liabilities75224259
Total current liabilities:121507088
Noncurrent Liabilities
Long-term debt and lease obligation36273117
Operating lease, liability36273117
Liabilities, other than long-term debt75833738
Deferred compensation liability, classified   1
Deferred income tax liabilities37362627
Other liabilities2221
Business combination, contingent consideration, liability3645109
Other undisclosed noncurrent liabilities61604728
Total noncurrent liabilities:17217011483
Total liabilities:293219184171
Stockholders' equity
Stockholders' equity attributable to parent1,026953968957
Common stock722718715711
Additional paid in capital35272215
Accumulated other comprehensive income012 
Retained earnings268208229231
Total stockholders' equity:1,026953968957
TOTAL LIABILITIES AND EQUITY:1,3191,1731,1521,129

Income statement (P&L) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Revenues139628203
Gross profit:139628203
Operating expenses(58)(34)(35)(45)
Operating income (loss):82(28)(7)158
Nonoperating income3353
Other nonoperating income (expense) (1)00
Income (loss) from continuing operations before income taxes:85(25)(2)161
Income tax expense (benefit)(25)4(0)(44)
Net income (loss) available to common stockholders, diluted:60(21)(2)117

Comprehensive Income ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Net income (loss):60(21)(2)117
Comprehensive income (loss):60(21)(2)117
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(2)2 
Comprehensive income (loss), net of tax, attributable to parent:60(23)(0)117

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: